Characteristics

Vimentin methylation

p

Negative (n = 32)

Positive (n = 18)

Age (years)

≤50

16 (50.0%)

9 (50.0%)

1.000

>50

16 (50.0%)

9 (50.0%)

Tumor size (cm)

<3

12 (37.5%)

5 (27.8%)

0.486

≥3

20 (62.5)

13 (72.2)

LN metastasis

Negative

17 (53.1%)

10 (55.6%)

Positive

15 (46.9%)

8 (44.4%)

Vas invasion

Positive

25 (78.1%)

14 (77.8%)

1.000

Negative

7 (21.9%)

4 (22.2%)

Her 2 neu

Negative

20 (62.5%)

11 (61.1%)

0.923

Positive

12 (37.5%)

7 (38.9%)

P R

Negative

11 (34.4%)

1 (5.6%)

0.036*

Positive

21 (65.6%)

17 (94.4%)

E R

Negative

12 (37.5%)

2 (11.1%)

0.046

Positive

20 (62.5%)

16 (88.9%)

Subtypes

TNBC

11 (34.4%)

0 (0.0%)

0.004*

Non TNBC

21 (65.6%)

18 (100.0%)

TNM stage

Stage II

17 (53.1%)

13 (72.2%)

0.186

Stage III

15 (46.9%)

5 (27.8%)

Serum vimentin (ng/ml)

1385.34 ± 537.25

688.89 ± 480.09

<0.001*

Serum Ca 15-3

53.38 ± 16.17

47.44 ± 13.03

0.190